Omeros Corporation Finalizes Asset Purchase and License Agreement with Novo Nordisk for MASP-3 Inhibitor Zaltenibart
Omeros Corporation Announces Completion of Asset Purchase and License Agreement with Novo Nordisk for Zaltenibart a Late-Stage MASP-3 Inhibitor Omeros Corporation today announced the successful closing of its previously disclosed…
Mirum Pharmaceuticals Begins BLOOM Phase 2 Trial with First Patient Dosed Evaluating MRM-3379 for Fragile X Syndrome
Mirum Pharmaceuticals Enrolls First Participant in BLOOM Phase 2 Study Evaluating MRM-3379 for Fragile X Syndrome Mirum Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and delivering innovative therapies for…
Incyte Names Richard Hoffman Executive Vice President and General Counsel
Incyte Announces Appointment of Richard Hoffman as Executive Vice President and General Counsel Incyte today announced that Richard Hoffman has officially assumed the role of Executive Vice President and General…
Circle Pharma Announces Appointment of Dr. Anne E. Borgman as CMO
Circle Pharma Appoints Anne E. Borgman, M.D., as Chief Medical Officer, Strengthening Leadership Team to Advance Next-Generation Macrocycle Oncology Pipeline Circle Pharma, Inc., a clinical-stage biopharmaceutical company advancing a new…
Agilent Unveils 21 CFR Part 11–Compliant Software for xCELLigence RTCA eSight
Agilent Launches Compliance Software for xCELLigence RTCA eSight to Meet 21 CFR Part 11 Standards Agilent Technologies Inc., a global leader in analytical instrumentation, diagnostics, and scientific innovation, has announced…
TeamBest Global Issues Open Letter to AROI on Affordable Cancer and Vascular Care
TeamBest Global Calls for Stronger Collaboration with AROI to Advance Affordable Cancer and Vascular Disease Care in India and Worldwide Dr. Krishnan Suthanthiran, along with his TeamBest Global family of…
Celltrion Wins Health Canada Approval for Eydenzelt Biosimilar
Celltrion Receives Health Canada Approval for Eydenzelt®, a Biosimilar Referencing Eylea® Celltrion, Inc. has announced a major regulatory milestone with the approval of Eydenzelt® by Health Canada. The newly approved…
African Leaders Urge Stronger Health Systems at ICASA 2025
AHF and Society for AIDS in Africa Convene High-Level Summit to Advance Regional Health Leadership and Sustainable Health Financing in Africa at ICASA 2025 The AIDS Healthcare Foundation (AHF) Global…
Corstasis and Cardiovascular Logistics Partner to Advance Outpatient Heart Failure Care
Corstasis Partners with Cardiovascular Logistics to Redefine Heart Failure Treatment Corstasis Therapeutics Inc., a commercial-stage biopharmaceutical company focused on advancing patient-centric, outpatient treatment strategies for cardiovascular and renal disorders, today…
FDA Grants Accelerated Approval to Otsuka’s VOYXACT for IgAN Proteinuria Reduction
Otsuka Announces FDA Accelerated Approval of VOYXACT® for Proteinuria Reduction in Adults with Primary IgA Nephropathy Otsuka Pharmaceutical Development & Commercialization, Inc., together with Otsuka Pharmaceutical Co., Ltd., announced that…
Arrowhead Pharmaceuticals Announces Full-Year 2025 Financial Results
Arrowhead Pharmaceuticals Reports Fiscal Year 2025 Financial Results and Highlights Major Regulatory and Clinical Milestones Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its financial results for the fiscal year ending…
Real-World Evidence Confirms Repatha’s Sustained Cardiovascular Benefits
Real-World Study Shows Durable Cardiovascular Protection with Repatha Target RWE, a leading organization in modern real-world evidence (RWE) generation and a trusted partner for regulatory-grade research, has announced significant new…